02-Jul-2026 16:23:23

ONESOURCE SPECIALTY PHARMA: US-FDA INSPECTION AT BENGALURU FACILITY CONCLUDES WITH ONE OBSERVATION

• A routine cGMP inspection was conducted by the USFDA at the Sterile Product Division facility in Bengaluru. • The inspection took place from June 22, 2026, to June 30, 2026. • The company will respond comprehensively to the FDA within the stipulated time frame. • Further developments will be informed to the stock exchanges. Impact: No significant impact on operations or future business expected.

Onesource Specialty Pharma Limited

← Back to feed